DAC group is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
==== PET imaging ==== Similar to MRI imaging, metal radionuclides can be loaded into nanogels and crosslinked to obtain PET radiotracers for imaging. Nanogels containing copper isotopes commonly used for PET imaging demonstrated overall stability and accumulation in tumors, which produced a higher signal in comparison to nearby tissue. Other studies have explored similar technologies with redox-responsive nanogels loaded with an isotope of gallium and other trivalent metals for PET imaging. Nanogels composed of dextran have also been developed for imaging tumor-associated macrophages with radionuclides and targeting the bone.
It was thought appropriate to choose a name to dissociate nicotinic acid from nicotine, to avoid the perception that vitamins or niacin-rich food contains nicotine, or that cigarettes contain vitamins. The resulting name niacin was derived from nicotinic acid + vitamin. Carpenter found in 1951, that niacin in corn is biologically unavailable, and can be released only in very alkaline lime water of pH 11. This explains why a Latin-American culture that used alkali-treated cornmeal to make tortilla was not at risk for niacin deficiency. The modern explanation is that alkali treatment enhances the bioavailability of tryptophan, not directly for any form of the vitamin. In 1955, Altschul and colleagues described large amounts of nicotinic acid as having a lipid-lowering property. As such, niacin is the oldest known lipid-lowering drug. Lovastatin, the first 'statin' drug, was first marketed in 1987.
== Biography == Stern was born and raised in Auvergne; her father is a Portuguese immigrant. After graduating secondary school and receiving her baccalauréat littéraire, she left Auvergne for Paris, where she studied visual arts at Paris 8 University Vincennes-Saint-Denis. She further studied architecture in Brussels.
continuously collect small fractions of the effluent from 1D, ensuring that the separation is maintained in this dimension; focus or refocus the effluent of a narrow band; to quickly transfer the 2D fraction collected and focused as a narrow pulse. Taken together, these three steps are called modulation cycle, which is repeated throughout the chromatographic run.
Sources: en.wikipedia.org
However, adapted TAILS and COFRADIC workflows have been developed specifically to study the C-termini of proteins. Recently, the Overall Lab tackled another difficulty of C-terminomics, using endopeptidase LysargiNase™ to generate C-termini carrying N-terminal lysine or arginine residues. Previously, C-termini lacked basic residues after endopeptidase digestion and could be missed in LC-MS/MS workflows. Another approach designed at further elucidating protease activity is Proteomic Identification of protease Cleavage Sites (PICS). Beginning with a peptide library generated from endopeptidase digestion of a proteome, this technique allows for screening and characterizing the prime- and non-prime specificity for proteases. After digestion, primary amines and sulfhydryl are chemically blocked before digesting the sample again with the desired protease. Now, protease generated primary amines that constitute the prime site of cleavage can be biotinylated and isolated due to their reactivity and analyzed by LC-MS/MS. Non-prime sides sequences left behind must be determined using bioinformatics analysis of the extracted N-termini and full length protein sequences. These prime and non-prime sites give a full picture of protease cleavage site specificity.
==== 2004 DOE panel ==== In August 2003, the U.S. Secretary of Energy, Spencer Abraham, ordered the DOE to organize a second review of the field. This was thanks to an April 2003 letter sent by MIT's Peter L. Hagelstein, and the publication of many new papers, including the Italian ENEA and other researchers in the 2003 International Cold Fusion Conference, and a two-volume book by U.S. SPAWAR in 2002. Cold fusion researchers were asked to present a review document of all the evidence since the 1989 review. The report was released in 2004. The reviewers were "split approximately evenly" on whether the experiments had produced energy in the form of heat, but "most reviewers, even those who accepted the evidence for excess power production, 'stated that the effects are not repeatable, the magnitude of the effect has not increased in over a decade of work, and that many of the reported experiments were not well documented'". In summary, reviewers found that cold fusion evidence was still not convincing 15 years later, and they did not recommend a federal research program. They only recommended that agencies consider funding individual well-thought studies in specific areas where research "could be helpful in resolving some of the controversies in the field". They summarized its conclusions thus:
=== Research === Orally administered açaí has been tested as a contrast agent for magnetic resonance imaging (MRI) of the gastrointestinal system. Its anthocyanins have also been characterized for stability as a natural food coloring agent.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.